Craif

Recent Finacing

Series C

Recent Raise

$22M

Craif develops a urine-based miRNA/exosome capture platform (NANO IP) and miSignal kits using nanofabrication and AI to noninvasively screen for early-stage multiple cancers via clinical, pharmacy, and DTC channels.